Wegovy for Heart Disease: What the SELECT Trial Means for Patients

Wegovy for Heart Disease: What the SELECT Trial Means for Patients

The link between excess body weight and heart health has been a cornerstone of medical advice for decades. Now, a groundbreaking clinical trial is adding a new dimension to this conversation, suggesting that a well-known weight management medication may also play a direct role in protecting the heart.

The study, called the SELECT trial, looked at Wegovy (the brand name for semaglutide 2.4 mg) and its effects on cardiovascular health. The results have generated significant discussion among doctors and patients alike. This article will break down what the study found, what it means for people living with heart disease, and how to approach this topic with your doctor. Consult your healthcare provider before starting any medication.

What is Wegovy?

Before diving into the trial, it’s helpful to understand the medication itself. Wegovy is an injectable prescription medicine that belongs to a class of drugs called GLP-1 receptor agonists.

Originally developed to help manage blood sugar in people with type 2 diabetes, GLP-1 medications were also found to have a significant effect on weight. They work by mimicking a natural hormone that targets areas of the brain involved in appetite regulation, helping you feel fuller longer and reducing food intake. Its primary, established use has been for chronic weight management in adults with obesity or overweight who also have at least one weight-related medical problem.

Unpacking the Landmark SELECT Trial

The SELECT trial was designed to answer a very specific and important question: Beyond weight loss, could semaglutide 2.4 mg actually reduce the risk of serious cardiovascular events in a high-risk population?

Who Was in the Study?

This is a critical piece of the puzzle. The trial enrolled over 17,500 adults from across the globe. The participants were:

• Aged 45 or older.
• Had a BMI of 27 or higher, classifying them as having overweight or obesity.
• Had pre-existing cardiovascular disease (for example, a prior heart attack, stroke, or peripheral artery disease).
• Crucially, they did not have a history of diabetes.

This last point is what makes the study so unique. It isolated the medication's effect in a population where heart risks were high, but not complicated by a diabetes diagnosis. Participants were randomly assigned to receive either a weekly injection of Wegovy or a placebo, and neither the patients nor their doctors knew which they were getting.

What Were the Key Findings?

After following participants for an average of 40 months, the results were clear and significant. The group receiving Wegovy had a 20% lower risk of experiencing a major adverse cardiovascular event (MACE) compared to the group receiving the placebo.

What is a MACE? It’s a combined measure of three critical outcomes:

1. Death from a cardiovascular cause.
2. A non-fatal heart attack.
3. A non-fatal stroke.

A 20% reduction in this combined risk is a substantial finding in cardiovascular medicine. Interestingly, the researchers noted that the cardiovascular benefits appeared to begin early and seemed to extend beyond what could be explained by weight loss alone. This suggests the medication may have other protective mechanisms, such as reducing inflammation or having direct positive effects on blood vessels, though more research is needed to understand this fully.

What Does This Mean for Patients?

The SELECT trial is more than just another data point; it represents a potential shift in how we approach the intersection of weight management and cardiovascular disease.

A Tool for Risk Reduction

For the first time, a medication approved for weight management has been shown to provide this level of cardiovascular protection in people with established heart disease but without diabetes. This moves the conversation beyond the number on the scale and toward a broader goal of long-term heart health and risk reduction. It positions Wegovy as a potential therapeutic tool for a specific group of high-risk patients, to be used alongside other established treatments.

Who Might Benefit Most?

The findings are most relevant to people whose health profile mirrors that of the study participants: adults with overweight or obesity who have a history of cardiovascular events. If you have had a heart attack or stroke and are also living with excess weight, this research is directly applicable to a potential conversation with your doctor about your comprehensive care plan.

Lifestyle Remains the Foundation

It is essential to remember that medication is not a substitute for a healthy lifestyle. In the SELECT trial, all participants received counseling on healthy eating and physical activity. These foundational pillars of heart health—a balanced diet, regular movement, stress management, and avoiding tobacco—remain as important as ever. A medication like Wegovy is designed to work with, not in place of, these crucial lifestyle habits.

Important Considerations and Next Steps

As with any medical treatment, there are important factors to consider before determining if it's the right choice for you.

Safety and Side Effects

The safety profile of Wegovy in the SELECT trial was consistent with previous studies. The most common side effects are gastrointestinal and can include nausea, diarrhea, vomiting, and constipation. These are often most pronounced when starting the medication or increasing the dose and tend to lessen over time for many people.

Having an Open Conversation with Your Doctor

The results of the SELECT trial provide a new and important topic to discuss with your healthcare team. This is not about asking for a specific drug, but about partnering with your doctor to create the best possible plan for your heart health.

Consider asking questions like:

• Based on my personal health history, what do these trial results mean for me?
• What are the potential benefits and risks of adding a medication like this to my current treatment plan?
• How would this medication fit with my other therapies and lifestyle goals?

This information can help you and your provider make a shared, informed decision that is right for your individual circumstances. Consult your healthcare provider before starting any medication.

The SELECT trial has opened a new door in the management of cardiovascular disease, highlighting the powerful connection between metabolic health and heart health. By understanding the evidence, we can all have more informed conversations and take proactive steps toward a healthier future.

Sources

1. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. The New England Journal of Medicine, 389(24), 2221–2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
2. Novo Nordisk. (2023, August 8). Wegovy® cardiovascular outcomes trial SELECT shows 20% reduction in MACE. [Press release]. https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=166301
3. American Heart Association. (2023, November 11). Weight-loss drug semaglutide cuts risk of heart attack, stroke and death from cardiovascular disease. https://www.heart.org/en/news/2023/11/11/weight-loss-drug-semaglutide-cuts-risk-of-heart-attack-stroke-and-death-from-cardiovascular-disease
4. U.S. National Library of Medicine. (2023). A Heart Disease Study to See How Semaglutide Works in People With Overweight or Obesity (SELECT). ClinicalTrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT03574597
5. Harvard Health Publishing. (2023, November 13). Major study finds Wegovy protects against heart attacks and strokes. https://www.health.harvard.edu/blog/major-study-finds-wegovy-protects-against-heart-attacks-and-strokes-202311132883